Skip to main content

Advertisement

Effectiveness of a early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants

Background

Vertically HIV-1-infected infants are at high risk of severe manifestations of the disease in the first year of life [1]. For this reason, we have elected, since 1996, to treat all infants born to HIV-1-infected mothers with a combination of 3 reverse transcriptase inhibitors as soon as the diagnosis of vertical transmission is established.

Material and methods

This is a cohort study of the effectiveness and tolerance of therapy in the 17 HIV-1-infected infants followed from birth in 3 belgian paediatric reference centres since 1996. All of them had been treated according to these guidelines.

Results

Treatment was initiated in all patients before 66 days of life. All but one were asymptomatic at initiation of therapy. Median follow-up was 56 months (range: 26-103). Twelve out of the 17 patients (70.6%), including 11/13 (85%) infants treated with the combination of zidovudine, lamivudine and nevirapine, experienced a complete viral suppression (<50 copies/mL) with their first drug regimen. Lack of compliance was acknowledged by the parents of 3 of the 5 infants whose initial regimen failed. At last follow-up, 12 patients were asymptomatic, two were CDC stage A and three were stage B; 15 had HIV-1 RNA levels of < 50 copies/mL and 14 had ≥25% CD4 lymphocytes. Among them 11 were still treated with their first line regimen (Figure 1). One child experienced a transient severe side effect, another child had clinical lipodystrophy and 4 developed hypercholesterolemia.

figure1

Figure 1

Conclusions

Early initiation of treatment with 3 reverse transcriptase inhibitors appeared to be highly effective in this cohort of vertically HIV-1 infected infants. Parental adherence is crucial to the effectiveness of therapy.

References

  1. 1.

    Gray L, Newell ML, Thorne C, Peckam C, Levy J: Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics. 2001, 108 (1): 116-22. 10.1542/peds.108.1.116.

Download references

Acknowledgements

The authors would like to thank the patients and their families for their collaboration. This study was funded by the Smiles Foundation, Belgium and Dr Van der Linden received a grant from the European AIDS Clinical Society.

Author information

Correspondence to Dimitri Van der Linden.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Van der Linden, D., Hainaut, M., Goetghebuer, T. et al. Effectiveness of a early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Retrovirology 5, P24 (2008). https://doi.org/10.1186/1742-4690-5-S1-P24

Download citation

Keywords

  • Lamivudine
  • Zidovudine
  • Nevirapine
  • Early Initiation
  • Viral Suppression